Table 1.
Clinical background, HBV genotype and BCP/PC mutation profiles of the patients studied
| Total (n = 403) | HB-ACLF (n = 75) | CHB (n = 328) | P value | |
|---|---|---|---|---|
| Gender (M/F) | 348/55 | 67/8 | 281/47 | 0.405 |
| Age (years) | 39 (18–75) | 39 (19–72) | 38 (18–75) | 0.273 |
| Total bilirubin (μmol/L) | 15.3 (3.8–1053) | 451.0 (191.1–1053) | 12.8 (3.8–77) | <0.001 |
| ALT (IU/L) | 50 (7–3774) | 569 (57–3774) | 41(7–665) | <0.001 |
| HBV DNA (logcps/mL) | 5.26 ± 1.6 | 5.3 ± 1.7 | 5.2 ± 1.6 | 0.702 |
| Prothrombin activity (%) | 75.0 (5.0–238.9) | 22.7 (5–42) | 87.4 (43.6–238.9) | <0.001 |
| Albumin | 41.5 ± 7.65 | 29.9 ± 3.45 | 44.2 ± 5.52 | <0.001 |
| Albumin/globulin ratio | 1.58 ± 0.46 | 1.23 ± 0.64 | 1.66 ± 0.36 | <0.001 |
| HBeAg+ | 223 (55.8%) | 29 (38.7%) | 194 (59.1%) | 0.001 |
| Anti-HBe+ | 122 (30.3%) | 27 (36.0%) | 95 (29.0%) | 0.231 |
| Genotype B | 77 (19.1%) | 23 (30.7%) | 54 (16.5%) | 0.009 |
| Genotype C | 323 (80.1%) | 52 (69.3%) | 271 (82.6%) | 0.009 |
| Genotype D | 3 (0.8%) | 0 | 3 (0.9%) | – |
| Wild type | 89 (22.1%) | 0 | 89 (27.1%) | <0.001 |
| T1753V (C/A/G) | 72 (17.9%) | 21 (28%) | 51 (15.5%) | 0.012 |
| T1754G | 11 (2.7%) | 3 (4.0%) | 8 (2.4%) | 0.193 |
| A1762T | 230 (57.1%) | 58 (77.3%) | 172 (52.4%) | <0.001 |
| G1764A | 239 (59.3%) | 62 (82.7%) | 177 (54.0%) | <0.001 |
| C1766T | 21 (5.2%) | 5 (6.7%) | 16 (4.9%) | 0.529 |
| T1768A | 10 (2.5%) | 2 (2.7%) | 8 (2.4%) | 0.584 |
| G1896A | 138 (34.2%) | 34 (45.3%) | 105 (32.0%) | 0.038 |
| G1899A | 34 (8.4%) | 12 (16.0%) | 22 (6.7%) | 0.013 |
HB-ACLF, hepatitis B-related acute-on-chronic liver failure; ALT, alanine aminotransferase; BCP, basal core promoter; CHB, chronic hepatitis B; HBV, hepatitis B virus; PC, precore.